Class / Patent application number | Description | Number of patent applications / Date published |
424530000 | Plasma | 62 |
20080286379 | Method and Means for Obtaining Platelet-Rich Plasma - Method and means for obtaining thrombocyte-rich plasma (platelet-rich plasma, PRP) from whole blood which specifically has a high content of specifically activated thrombocytes and which is particularly easy to coagulate. | 11-20-2008 |
20080299212 | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum - The present invention relates to a pharmaceutical agent for treating Avellino corneal dystrophy, and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy comprising pharmaceutically effective amount of blood plasma or serum as an active ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms by dissolving away hyaline granules in the cornea of a patient with severe Avellino corneal dystrophy due to LASIK surgery. | 12-04-2008 |
20080305178 | USE OF A HIGH MOLECULAR WEIGHT EXTRACELLULAR HAEMOGLOBIN AS A BLOOD SUBSTITUTE - A blood substitute, of an extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million daltons, comp sing chains of polymerised globins, containing free cysteines capable of binding to NO and/or SNO groups, and having a P | 12-11-2008 |
20090035382 | METHOD AND COMPOUND FOR THE TREATMENT OF ARTICULAR DISEASES OR ARTICULAR PAIN, OR FOR THE TREATMENT OF SKIN FOR AESTHETIC OR OTHER PURPOSES, AND THE METHOD OF PREPARATION OF THE COMPOUND - Method for the treatment of articular diseases or articular pain, or for the treatment of skin, which comprises the infiltration or the application of a compound that comprises at least one blood-derived substance, which is preferably a blood plasma in general, and in particular a platelet-rich plasma (PRP), and preferably a plasma rich in growth factors (PRGF), and/or a supernatant of any of the aforementioned plasmas. The inventive method enables the significant relief and even regeneration of the treated areas. Optionally, the blood-derived substance may be mixed with hyaluronic acid (HA) and/or an HA-derived compound, thereby achieving even more beneficial effects. | 02-05-2009 |
20090092678 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 04-09-2009 |
20090092679 | PARTICLE/CELL SEPARATION DEVICE AND COMPOSITIONS - A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted. | 04-09-2009 |
20090136587 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NERVE DAMAGE COMPRISING BLOOD PLASMA OR SERUM - The present invention relates to a pharmaceutical composition for the treatment of nerve damage, and more particularly to a pharmaceutical composition for the treatment of nerve damage, which contains blood plasma or serum as an active ingredient. The inventive composition regenerates nerve cells after spinal nerve damage and provides complete structural continuity in the spinal nerve lesion sites. Thus, the composition is useful for the treatment of nerve damage. | 05-28-2009 |
20090196938 | USE OF A MATRIX FOR REMOVING C-REACTIVE PROTEIN FROM BIOLOGICAL FLUIDS - The present invention relates to a method for treating the risk of increased C-reactive protein (CRP) levels by conducting extracorporeal perfusion of blood plasma from patients with risk for cardiovascular diseases or immune dysfunctions, such as autoimmune diseases, through a device, such as a column, which contains absorbent matrix material including lipids, peptides, polypeptides, phosphocholine (PC) or PC derivatives so as to remove C-reactive protein. Moreover, the present invention relates to the use of compounds which have the characteristic to bind CRP at least temporarily, for removing CRP from biological fluids of a patient for prophylaxis and/or treatment of autoimmune diseases, cardiovascular diseases, such as infarction, stroke, diabetes, rheuma and renal failure. | 08-06-2009 |
20090317483 | Bicomponent Bioadhesive for Biomedical Use - The invention relates to new biocomponent bioadhesive formulations, with a synthetic part and an autologous biological part of blood origin comprising plasma rich in platelets and in growth factors, and its use of same in biomedicine, preferably in opththalmic surgery. | 12-24-2009 |
20100112081 | USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIES - Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur. | 05-06-2010 |
20100159023 | METHOD FOR STABILISING BLOOD PLASMA COMPONENTS IN A LYOPHILISATE - Process for the stabilization of blood plasma components in a lyophilizate, wherein
| 06-24-2010 |
20100189802 | Method for treatment of vascular hyperpermeability - A method comprising preparing a vascular hyperpermeability treatment composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof in a form deliverable to a mammal; whereby an effective amount of the composition raises the threshold for apoptosis and/or prevents or lessens the occurrence of vascular hyperpermeability. A method comprising preventing hyperpermeability associated with hemorrhagic shock via preparing a composition in a form deliverable to a mammal, the composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof; and raising the threshold for apoptosis in a mammal's endothelial cells by administering an effective amount of said antioxidant; whereby said raising the threshold for apoptosis prevents said hyperpermeability. | 07-29-2010 |
20100196497 | Method of Treating Tissue Using Platelet-Rich Plasma in Combination with Low-Level Laser Therapy - This invention is a method of treating a patient's injured tissue by applying platelet-rich plasma and laser energy to the injured tissue. The applied energy is low-level, and the patient feels no sensation of the low-level laser energy being applied. The laser energy can be applied before, after, or during the platelet-rich plasma application, or any combination thereof. Additional laser therapy may be applied over the entire extremity containing the injury, any non-injured adjacent tissue, as well as to the patient's entire body for stimulation of other body systems. Additionally, laser energy can be applied to the platelet-rich plasma before the platelet-rich plasma is applied to the patient. | 08-05-2010 |
20100233282 | DEVICE AND METHODS FOR DELIVERY OF BIOACTIVE MATERIALS TO THE RIGHT SIDE OF THE HEART - A method of delivering a bioactive composition to the right side of the heart is described. The method can be used to treat cardiac dysfunction such as myocardial infarction, arrhythmias or congestive heart failure. A dual lumen catheter is described for delivering the bioactive substance by inserting a first cannula of a dual lumen catheter into a vein to access the right ventricle. The first cannula has a first balloon which is blown up proximal to the tricuspid valve. A second cannula is then introduced which accesses the right side of the heart and coronary sinus. The bioactive substance is then delivered to the right side of the heart. The bioactive substance may include platelets and/or white blood cells at concentrations higher than what is normally found in whole blood. | 09-16-2010 |
20100285146 | PEPTIDES AND METHODS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38 (SEQ. ID. NO. 1), and claimed R38 analogs and derivatives thereof including 5200 (SEQ. ID. NO. 10), 5104 (SEQ. ID. NO. 15), 5105 (SEQ. ID. NO. 16), 5106 (SEQ. ID. NO. 17), 5107 (SEQ. ID. NO. 18), 5108 (SEQ. ID. NO. 19), 5109 (SEQ. ID. NO. 20), 5110 (SEQ. ID. NO. 21). The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. The invention also provides assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom. In addition, the subject invention concerns a method of treating systemic lupus erythematosus in a subject comprising the extracorporeal removal of lupus antibodies from the subject's plasma and returning the plasma to the subject. In an additional aspect, the invention provides method of reducing anti-R38 antibody levels in a patient's plasma. | 11-11-2010 |
20100323029 | FIVE-COORDINATE NEUROGLOBIN AND USE THEREOF AS A BLOOD SUBSTITUTE - Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood. | 12-23-2010 |
20110008458 | Process for removing growth factors from platelets - A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure. | 01-13-2011 |
20110008459 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 01-13-2011 |
20110104298 | Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma - A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized in that | 05-05-2011 |
20110111049 | Ischemia/reperfusion protection compositions and methods of using - The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery. | 05-12-2011 |
20110280952 | Platelet Lysate and Bioadhesive Compositions Thereof for the Treatment of Mucositis - The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described. | 11-17-2011 |
20120003324 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 01-05-2012 |
20120027867 | Spray-Dried Blood Products and Methods of Making Same - The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above. | 02-02-2012 |
20120045518 | ENHANCING COAGULATION OR REDUCING FIBRINOLYSIS - Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma). | 02-23-2012 |
20120087988 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY CONDITIONS USING PLATELET ENRICHED PLASMA - Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system. | 04-12-2012 |
20120087989 | USE OF GELLED PRP (PLATELET GEL) FOR VOLUMETRIC BREAST RECONSTRUCTION - The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants. | 04-12-2012 |
20120114760 | COMPOSITIONS FOR TREATING WOUNDS AND PROCESSES FOR THEIR PREPARATION - Embodiments of the invention are directed to methods of treating a wound by administering a wound-healing composition and the wound-healing composition. The wound-healing composition has a purified platelet-removed platelet-rich plasma and a wound-healing component. The wound-healing component is a protein, a peptide, or combinations thereof. The methods of treatment utilize an amount of the wound-healing composition sufficient to treat a patient with a wound, which may occur by promoting an activity of cell migration, cell proliferation, and/or angiogenesis. Also disclosed are processes for preparing the wound-healing composition. | 05-10-2012 |
20120141593 | METHODS OF INCREASING PRODUCTIVITY IN OLDER SOWS WHILE DECREASING FEED INTAKE - The present invention provides methods for feeding older sows that beneficially reduce feed intake in older sows, yet improve pig survival and weaning weight of pigs from older sows. | 06-07-2012 |
20120201896 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 08-09-2012 |
20120201897 | COMPOSITION FOR INDUCING TISSUE REGENERATION BY ACTIVATING PLATELET-RICH PLASMA (PRP), AND METHOD FOR MANUFACTURING SAME - The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration. | 08-09-2012 |
20120263796 | ANTI-VLA-4 RELATED ASSAYS - Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level. | 10-18-2012 |
20130028980 | CELL-POLYMER FIBER COMPOSITIONS AND USES THEREOF - The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-β-1→4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving hemostasis. | 01-31-2013 |
20130045279 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION - The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain. | 02-21-2013 |
20130122107 | Freeze-Dried Plasma Formats for the Trauma Care Field - Disclosed are freeze-dried plasma formats specifically designed for the trauma care field. Blood plasma is subjected to a glucose removal step, a protein fraction up-concentration step and addition of stabilizers prior to freeze-drying. Preferable stabilizers are glutamine dipeptides, glutamine and glycine. The glutamine based formulation is added direct to plasma and serves three main purposes: 1) Increases stability of plasma proteins and stabilizes pH in freeze-dried state; 2) Increases stability of plasma proteins against Gamma Irradiation and thus allows for the application of a terminal sterilization step; 3) Introduces supplements beneficial to the trauma patient. | 05-16-2013 |
20130189370 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 07-25-2013 |
20130216626 | PLATELET-RICH PLASMA COMPOSITIONS - The present invention relates to a method of treating functional disability and/or pain associated with joints, tendons or connective tissue diseases, disorders or injuries comprising oral administration of a composition comprising heterologous platelet-rich plasma. The invention also relates to pharmaceutical compositions and nutritional compositions comprising heterologous platelet-rich plasma and uses thereof. | 08-22-2013 |
20130230599 | Spray Dried Human Plasma - The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma power, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder. | 09-05-2013 |
20130236560 | METHODS OF INCREASING PRODUCTIVITY IN OLDER SOWS WHILE DECREASING FEED INTAKE - The present invention provides methods for feeding older sows that beneficially reduce feed intake in older sows, yet improve pig survival and weaning weight of pigs from older sows. | 09-12-2013 |
20130243877 | Spray-Dried Human Plasma - The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma power, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder. | 09-19-2013 |
20130243878 | BIOMATERIALS FOR DELIVERY OF BLOOD EXTRACTS AND METHODS OF USING SAME - The disclosure provides biomaterials including scaffolds that include blood products including blood fractions and products including platelets for administration to subjects in need thereof. More specifically, the scaffolds based on step growth polymers are enriched with blood extracts that contain platelet rich plasma (PRP) and/or extracts of platelets. Compositions comprising a biomaterial or precursor thereof and a blood extract are provided, as are methods of making and using the biopolymers or precursors thereof. Kits and articles of manufacture comprising the biopolymers or precursors thereof are also described. | 09-19-2013 |
20130243879 | PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF - Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy. | 09-19-2013 |
20130280342 | System and Method for Collecting Platelets and Anticipating Plasma Return - A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump. The blood component separation device separates the drawn blood into a first blood component and a second blood component, and sends the first blood component to a first blood component bag. The first return line fluidly connects the venous-access device and the blood component separation device. The recirculation line connects the first blood component container and the separation device. The second return line fluidly connects the first blood component container and the first return line and is configured to return the first blood component within the first blood container to the subject. | 10-24-2013 |
20140044795 | COMPOSITION WITH GROWTH FACTORS, TO BE USED IN THE INTRANASAL TREATMENT OF A NEURODEGENERATIVE DISEASE OR OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM, AND ITS METHOD OF MANUFACTURE - The object of the invention is the treatment of neurodegenerative diseases or other applicable diseases by means of the intranasal administration of a composition obtained from at least one growth-factor-containing blood compound, or by means of a therapeutic substance obtained from said composition, in addition to the composition itself. It is guaranteed that the composition reaches the central nervous system in an effective manner in terms of the treatment, and also in a safe manner for the patient. | 02-13-2014 |
20140044796 | DETECTION AND REMOVAL OF MISFOLDED PROTEINS/PEPTIDES - The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives. Furthermore the invention includes substances to identify and methods to detect bio-films, a method to examine hemocompatibility of materials and a method to optimize therapeutical products, and to provide reagents microorganisms to charge with for more reliable diagnostics and quality control of biopharmaceuticals and identification substances for the screening for preliminary stages of amyloids that can be used for technical purposes. | 02-13-2014 |
20140044797 | PROSTACYCLIN AND ANALOGS THEREOF ADMINISTERED DURING SURGERY FOR PREVENTION AND TREATMENT OF CAPILLARY LEAKAGE - The present invention relates to the novel use of prostacyclin analogs for prevention and/or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment. | 02-13-2014 |
20140105997 | GALECTIN-3 PLASMAPHERESIS THERAPY - The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer. | 04-17-2014 |
20140161899 | METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS - The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine proteaseper ml of the plasma fraction. | 06-12-2014 |
20140186455 | Tissue repair system - An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid. The fiber component typically will have short fiber lengths, so as to avoid forming entangled masses or clumps when mixed with a fluid. In an embodiment, the fiber material is native collagen fibers and the settable fluid is an isolated blood fraction, such as platelet rich plasma and platelet poor plasma. The native collagen fiber retaining the native crosslinks of the source tissue and providing an architectural and structural scaffolding for advancing cellular infiltration. The wound healing implant will accelerate the bodies healing process, to provide better healing and less scar tissue of the wound site. | 07-03-2014 |
20140234432 | ENHANCING COAGULATION OR REDUCING FIBRINOLYSIS - Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichlororuthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma). | 08-21-2014 |
20140242181 | PREPARATION OF FIBRIN GEL FOR USE AS IMPLANT SYSTEM - The present invention aims to generate a fibrin gel for cell proliferation and transport using the patient's own blood or compatible blood. The gel-preparation process consists in taking a quantity of blood from the patient, using sodium citrate as anticoagulant, separating off the citrated plasma by centrifugation, and resuspending the cells to be transported in the plasma. CaCl | 08-28-2014 |
20150037430 | FORMULATION OF A BLOOD COMPOSITION THAT IS RICH IN PLATELET AND/OR GROWTH FACTORS AND CONTAINS GELLED PROTEINS, AND A METHOD FOR ITS PREPARATION - Formulation comprising, or derived from, an initial blood composition, wherein the formulation is rich in platelets and/or growth factors and proteins originating from the initial blood composition, and wherein the proteins are in a gelled state. The invention also refers to method for preparing the formulation, comprising the steps of heating and then cooling the initial blood composition at certain temperatures and times. Among other advantages, the formulation in accordance with the invention is biocompatible and biodegradable, presents the desirable biological or medical properties provided by the presence of platelets or growth factors, and also presents high dimensional stability over time. | 02-05-2015 |
20150037431 | USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIES - Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. | 02-05-2015 |
20150079194 | SYSTEMS, COMPOSITIONS, AND METHODS FOR TRANSPLANTATION AND TREATING CONDITIONS - Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds. | 03-19-2015 |
20150306183 | FIVE-COORDINATE NEUROGLOBIN AND USE THEREOF AS A BLOOD SUBSTITUTE - Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood. | 10-29-2015 |
20150359770 | AMINO ACID IMPROVING SENSITIVITY OF BATCTERIA TO SERUM - Glycine, threonine, and serine can enhance the sensitivity of bacteria to serum, plasma, or whole blood, and therefore can be used as molecules to improve the bactericidal effect of the serum, the plasma, or the whole blood. | 12-17-2015 |
20160030416 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA - Methods of treating B | 02-04-2016 |
20160082044 | FORMULATIONS AND METHODS FOR CONTEMPORANEOUS STABILIZATION OF ACTIVE PROTEINS DURING SPRAY DRYING AND STORAGE - A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention. | 03-24-2016 |
20160089423 | COMPOSITIONS AND METHODS FOR TREATING POST-OPERATIVE COMPLICATIONS OF CARDIOPULMONARY SURGERY - Disclosed herein are compositions and methods for treating damage inflicted by use of a cardio-pulmonary bypass (CPB) machine, particularly excessive bleeding and multi organ failure, by administering a pharmaceutical composition comprising alpha-1 antitrypsin (AAT). | 03-31-2016 |
20160113965 | Spray Dried Human Plasma - The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder. | 04-28-2016 |
20160120955 | COMPOSITIONS COMPRISING COLLAGEN AND PRP FOR TISSUE REGENERATION - A composition of matter is disclosed which comprises crosslinked collagen, platelet rich plasma (PRP) and an inorganic salt. Methods of generating same and uses thereof are also disclosed. | 05-05-2016 |
20160184360 | COMPOSITION WITH GROWTH FACTORS, TO BE USED IN THE INTRANASAL TREATMENT OF A NEURODEGENERATIVE DISEASE OR OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM, AND ITS METHOD OF MANUFACTURE - The object of the invention is the treatment of neurodegenerative diseases or other applicable diseases by means of the intranasal administration of a composition obtained from at least one growth-factor-containing blood compound, or by means of a therapeutic substance obtained from said composition, in addition to the composition itself. It is guaranteed that the composition reaches the central nervous system in an effective manner in terms of the treatment, and also in a safe manner for the patient. | 06-30-2016 |
20160184363 | METHOD FOR ISOLATION AND PURIFICATION OF MICROVESICLES FROM CELL CULTURE SUPERNATANTS AND BIOLOGICAL FLUIDS - The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles. | 06-30-2016 |